BamSEC and AlphaSense Join Forces
Learn More

BridgeBio Pharma Inc. – Material Contracts

NASDAQ: BBIO    
Share price (8/11/26): $83.70    
Market cap (8/11/26): $16.4 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 20 pages Registration Rights Agreement of BridgeBio Pharma, Inc. Dated as of July 1, 2026
12/34/56
EX-10.1
from 8-K 42 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Investment Agreement Dated as of July 1, 2026 by and Among BridgeBio Pharma, Inc. and the Purchasers Identified Herein
12/34/56
EX-10.1
from 8-K 51 pages BridgeBio Pharma, Inc. Third Amended and Restated 2021 Stock Option and Incentive Plan
12/34/56
EX-10.2
from 10-Q 2 pages Amendment No. 5 to Consulting Agreement
12/34/56
EX-10.1
from 10-Q 15 pages BridgeBio Pharma, Inc. Amended and Restated 2019 Employee Stock Purchase Plan
12/34/56
EX-10.25
from 10-K 3 pages BridgeBio Pharma, Inc. Amended and Restated Director Compensation Policy Effective Date: December 11, 2025
12/34/56
EX-10.17
from 10-K 2 pages Amendment No. 4 to Consulting Agreement
12/34/56
EX-10.16
from 10-K 2 pages Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.2
from 10-Q 117 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. First Amendment to Funding Agreement
12/34/56
EX-10.1
from 10-Q 72 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Royalty Interest Purchase and Sale Agreement by and Among Eidos Therapeutics, Inc., as the Company and BridgeBio Pharma, Inc., as the Parent, on the One Hand and Acoramidis Royalty Spv, LP and Lsi Financing Fund, LP, as the Purchasers and Acoramidis Royalty Spv, LP, as the Purchaser Representative, on the Other Hand Dated June 27, 2025
12/34/56
EX-10.1
from 8-K 51 pages BridgeBio Pharma, Inc. Second Amended and Restated 2021 Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 7 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential. Consulting Agreement
12/34/56
EX-10.42
from 10-K 5 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 8-K 91 pages Amended and Restated Limited Liability Company Agreement of Bridgebiox Pharma, LLC, a Delaware Limited Liability Company Dated as of August 16, 2024
12/34/56
EX-10.1
from 8-K 75 pages Transaction Agreement Dated as of August 16, 2024 by and Among
12/34/56
EX-10.2
from 10-Q 70 pages 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.1
from 10-Q 163 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Second Amendment to Financing Agreement
12/34/56
EX-10.1
from 8-K 12 pages 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan
12/34/56
EX-10.7
from 10-Q 4 pages Amendment No. 3 to Consulting Agreement
12/34/56
EX-10.6
from 10-Q 4 pages Amendment № 3 to the Exclusive (Equity) Agreement Effective the 10th Day of April 2016 Between the Board of Trustees of the Leland Stanford Junior University and Eidos Therapeutics, Inc
12/34/56